Lit Matters 2: TXA for trauma, good, bad, or neither?

Traumatic hemorrhage kills early, and tranexamic acid appears to improve survival without a signal for more vascular occlusive events. The benefit is strongest when TXA is given early after injury, with especially compelling data in prehospital trauma and selected traumatic brain injury populations.

TXA in Acute Trauma Care

• Hyperfibrinolysis target: TXA works by blocking fibrin clot breakdown, a key mechanism when trauma-associated hyperfibrinolysis drives ongoing bleeding and early death.
• Mortality benefit signal: Across randomized emergency-setting trials, TXA was associated with lower 1-month mortality, with an absolute risk reduction of about 1.7%.
• Early treatment advantage: Time matters: the strongest signal favors TXA given as early as possible after injury, with benefit fading when administration is delayed. We get into the timing nuances in the episode.
• Twenty-four hour survival: In trials reporting early outcomes, TXA improved 24-hour mortality, supporting its role in the initial resuscitation window rather than as a late rescue.
• Thrombotic safety profile: Major vascular occlusive events such as MI, stroke, DVT, and PE were not increased at 1 month in the pooled randomized data.
• Prehospital and TBI signal: The effect may be more pronounced before hospital arrival, with out-of-hospital treatment showing a lower number needed to treat than in-hospital use, while TBI benefit appears strongest in mild to moderate injury.